Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Jiang (Shanghai, China), F. Wang (Qingdao, China), X. Liu (Shanghai, China). Danshenextract salt Inhibits bleomycin-induced experimental pulmonary fibrosis. 3381

Member's Comments

No comment yet.

Related content which might interest you: Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Effects of drotrecogin-alpha on the bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Expression of TGF-β and TGFβ receptors in bleomycin-induced pulmonary fibrosis of rats Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 Effect of curcumin on inflammation in experimental pulmonary fibrosis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 The effect of interferon-γ on bleomycin-induced alveolitis and pulmonary fibrosis in rats Source: Eur Respir J 2005; 26: Suppl. 49, 81s Year: 2005 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006 Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Aerobic training inhibits bleomycin-induced pulmonary fibrosis in BALB/c mice Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014